He also leads the Cambridge Clinical MS Research Group, a team dedicated to developing treatments that can repair myelin and reverse disability in MS.

MS is a lifelong neurological condition affecting over 150,000 people in the UK, causing progressive disability through immune-mediated damage to myelin, the protective sheath surrounding nerve fibres. For decades, treatments have focused on suppressing this inflammation, but many people with MS still experience worsening disability over time.

The group's research focuses on the next frontier in MS treatment: remyelination. The team runs innovative clinical trials testing whether repurposed drugs, including the diabetes medicine metformin and the antihistamine clemastine, can stimulate the brain's own stem cells to repair damaged myelin and reverse disability. They are also investigating immunotherapy approaches for autoimmune conditions of the brain.

Supporting this research will help unlock treatments that go beyond controlling MS to actively repairing the damage it causes.

Next steps

You can support this research by giving a gift online now or to discuss your philanthropic objectives, please contact: